Veriheal

NOVEMBER 30, 2021

Veriheal does not support illegally consuming therapeutic substances such as psilocybin but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. In 2008, he published psychedelic safety guidelines.

Research and Development 98

Research and Development Therapy Data Treatment 98

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., Dr. Wakshlag is currently available for interviews to discuss the results of the safety study as well as his clinical trials.

Safety 45

Safety CBD Clinical Trials Oil 45

Veriheal

OCTOBER 1, 2020

In 2004, cannabis was reclassified as a class C drug but was reinstated to Class B in 2008 following Prime Minister Gordon Brown’s decision to go against the advice offered up by the Advisory Council on the Misuse of Drugs. . Cannabis is easily accessible, and the regulations are loosening up quite a bit.

Legalization 104

Legalization Oil Medicine Media 104

Canna Law Blog

OCTOBER 28, 2019

Seems like not a month goes by in California where the Assembly isn’t trying to pass a slew of cannabis bills to help regulate the state’s industry under the Medicinal and Adult-Use Cannabis Regulation and Safety Act (“MAUCRSA”). And October was no different. ” Vape Cartridges and Pens.

Research and Development 51

Research and Development Programs Retail Vaping 51

SpeedWeed

AUGUST 10, 2021

Many regulated markets mandate indoor cultivation of marijuana for “security” and “safety” reasons, but the downside is that more energy is needed to support this type of production. Reduce energy consumption. Without access to the sun, indoor plants require energy-intensive grow lights. Support companies doing the work.

Packaging 52

Packaging Environment Cultivation Hash 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. The review, however, did not cover patient access to medicinal cannabis. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

JANUARY 13, 2023

Treating migraine pain is one of the instances where inhaled cannabis consumption, such as smoking or vaping , is important for the right effects and speed of delivery. 4 A 2004 study found that the endocannabinoid anandamide can inhibit trigeminal neurons, which suggests a way in which endocannabinoids may be able to prevent migraines.

Terpenes 132

Terpenes Strains THC Treatment 132